Header Logo

Connection

Usman Baber to Drug-Eluting Stents

Back to Details
This is a "connection" page, showing publications Usman Baber has written about Drug-Eluting Stents.
Usman Baber
Connection Strength
17.097
Drug-Eluting Stents
  1. Antiplatelet Therapy for Patients Who Have Undergone Revascularization Within the Past Year: Which Agents and for How Long? Med Clin North Am. 2024 May; 108(3):539-551.
    View in: PubMed
    Score: 0.809
  2. Polymer-Based Versus Polymer-Free Stents in High Bleeding Risk Patients: Less Is Not Always More. JACC Cardiovasc Interv. 2022 06 13; 15(11):1164-1166.
    View in: PubMed
    Score: 0.726
  3. Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI: TWILIGHT-SYNERGY. Catheter Cardiovasc Interv. 2021 01 01; 97(1):63-71.
    View in: PubMed
    Score: 0.631
  4. Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Circ Cardiovasc Interv. 2019 07; 12(7):e007734.
    View in: PubMed
    Score: 0.592
  5. The Challenge of Diabetes Mellitus in the Contemporary Percutaneous Coronary Intervention Era: Are We Making Progress? JACC Cardiovasc Interv. 2018 12 24; 11(24):2477-2479.
    View in: PubMed
    Score: 0.570
  6. Left Main PCI With DES Versus CABG: Cautionary Note or Cause for Concern? J Am Coll Cardiol. 2018 12 11; 72(23 Pt A):2823-2825.
    View in: PubMed
    Score: 0.569
  7. Defining PCI complexity in the contemporary DES era: Clarity or confusion? Int J Cardiol. 2018 10 01; 268:94-95.
    View in: PubMed
    Score: 0.561
  8. Improving Outcomes in High-Risk Percutaneous Coronary Interventions and Newer-Generation Drug-Eluting Stents: Good, But Not Good Enough. Cardiology. 2017; 138(2):73-75.
    View in: PubMed
    Score: 0.513
  9. Comparisons of the uptake and in-hospital outcomes associated with second-generation drug-eluting stents between men and women: results from the CathPCI Registry. Coron Artery Dis. 2016 Sep; 27(6):442-8.
    View in: PubMed
    Score: 0.486
  10. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. J Am Coll Cardiol. 2016 May 17; 67(19):2224-2234.
    View in: PubMed
    Score: 0.473
  11. Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2016 Jan 11; 9(1):28-38.
    View in: PubMed
    Score: 0.465
  12. The Shifting Pendulum for DAPT After PCI: Balancing Long-Term Risks for Bleeding and Thrombosis. J Am Coll Cardiol. 2015 Sep 01; 66(9):1046-9.
    View in: PubMed
    Score: 0.453
  13. DAPT duration after DES: what is the "mandatory" duration? J Am Coll Cardiol. 2015 Mar 24; 65(11):1103-6.
    View in: PubMed
    Score: 0.440
  14. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol. 2011 Oct 04; 58(15):1569-77.
    View in: PubMed
    Score: 0.344
  15. Stenting of complex lesions: an overview. Nat Rev Cardiol. 2010 Sep; 7(9):485-96.
    View in: PubMed
    Score: 0.321
  16. Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents. J Invasive Cardiol. 2010 Feb; 22(2):80-3.
    View in: PubMed
    Score: 0.308
  17. Stent Failure After Percutaneous Coronary Intervention in Diabetes?Mellitus: Does Glycemic Control Matter? J Am Coll Cardiol. 2024 Jul 16; 84(3):273-275.
    View in: PubMed
    Score: 0.210
  18. Prognostic impact of peripheral artery disease in patients with and without high bleeding risk undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2024 Feb; 103(3):425-434.
    View in: PubMed
    Score: 0.203
  19. Prognostic impact of in-stent restenosis in normal weight, overweight, and obese patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2024 Feb; 103(2):260-267.
    View in: PubMed
    Score: 0.202
  20. Intravascular imaging guided versus coronary angiography guided percutaneous coronary intervention: systematic review and meta-analysis. BMJ. 2023 11 16; 383:e077848.
    View in: PubMed
    Score: 0.200
  21. Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. EuroIntervention. 2022 Mar 18; 17(16):1330-1339.
    View in: PubMed
    Score: 0.178
  22. Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy. JACC Cardiovasc Interv. 2022 02 14; 15(3):282-293.
    View in: PubMed
    Score: 0.176
  23. Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. Eur Heart J. 2021 12 01; 42(45):4683-4693.
    View in: PubMed
    Score: 0.175
  24. One-Year COMBO Stent Outcomes in Acute Coronary Syndrome: from the COMBO Collaboration. Cardiovasc Drugs Ther. 2021 04; 35(2):309-320.
    View in: PubMed
    Score: 0.165
  25. A sex paradox in clinical outcomes following complex percutaneous coronary intervention. Int J Cardiol. 2021 04 15; 329:67-73.
    View in: PubMed
    Score: 0.163
  26. Impact of High-Density Lipoprotein Levels on Cardiovascular Outcomes of Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol. 2020 12 15; 137:1-6.
    View in: PubMed
    Score: 0.161
  27. Influence of final kissing balloon inflation on long-term outcomes after PCI of distal left main bifurcation lesions in the EXCEL trial. EuroIntervention. 2020 Jun 25; 16(3):218-224.
    View in: PubMed
    Score: 0.158
  28. One-year outcomes of patients undergoing complex percutaneous coronary intervention with three contemporary drug-eluting stents. Catheter Cardiovasc Interv. 2021 06 01; 97(7):1341-1351.
    View in: PubMed
    Score: 0.158
  29. Comparison of One-Year Outcomes in Patients >75 Versus =75 Years With Coronary Artery Disease Treated With COMBO Stents (From The MASCOT Registry). Am J Cardiol. 2020 07 15; 127:1-8.
    View in: PubMed
    Score: 0.156
  30. 1-Year Clinical Outcomes of All Comers Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents: Propensity Score-Matched Comparison of the COMBO and Ultrathin-Strut Orsiro Stents. JACC Cardiovasc Interv. 2020 04 13; 13(7):820-830.
    View in: PubMed
    Score: 0.156
  31. Sex differences in 1-year clinical outcomes after percutaneous coronary intervention with COMBO stents: From the COMBO collaboration. Catheter Cardiovasc Interv. 2021 04 01; 97(5):797-804.
    View in: PubMed
    Score: 0.155
  32. Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies. Circulation. 2020 03 17; 141(11):891-901.
    View in: PubMed
    Score: 0.154
  33. 1-year results after PCI with the COMBO stent in all-comers in Asia versus Europe: Geographical insights from the COMBO collaboration. Int J Cardiol. 2020 05 15; 307:17-23.
    View in: PubMed
    Score: 0.154
  34. Bayes Factor Meta-Analysis of the Mortality Claim for Peripheral Paclitaxel-Eluting Devices. JACC Cardiovasc Interv. 2019 12 23; 12(24):2528-2537.
    View in: PubMed
    Score: 0.153
  35. Ventricular Fibrillation Associated With Coronary Plaque Erosion Detected by Optical Coherence Tomography. JACC Cardiovasc Interv. 2020 01 13; 13(1):e5-e7.
    View in: PubMed
    Score: 0.152
  36. Impact of stent diameter on outcomes following percutaneous coronary intervention with second-generation drug-eluting stents: Results from a large single-center registry. Catheter Cardiovasc Interv. 2020 09 01; 96(3):558-564.
    View in: PubMed
    Score: 0.150
  37. Effect of stent diameter in women undergoing percutaneous coronary intervention with early- and new-generation drug-eluting stents: From the WIN-DES collaboration. Int J Cardiol. 2019 07 15; 287:59-61.
    View in: PubMed
    Score: 0.145
  38. Safety and Efficacy of Polymer-Free Drug-Eluting Stents. Circ Cardiovasc Interv. 2019 02; 12(2):e007311.
    View in: PubMed
    Score: 0.144
  39. Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry. Int J Cardiol. 2019 05 15; 283:67-72.
    View in: PubMed
    Score: 0.143
  40. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. Circ Cardiovasc Qual Outcomes. 2019 01; 12(1):e004945.
    View in: PubMed
    Score: 0.143
  41. 1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent: Primary Results of the COMBO Collaboration. JACC Cardiovasc Interv. 2018 10 08; 11(19):1969-1978.
    View in: PubMed
    Score: 0.141
  42. Intravascular Brachytherapy for the Management of Repeated Multimetal-Layered Drug-Eluting Coronary Stent Restenosis. Circ Cardiovasc Interv. 2018 10; 11(10):e006832.
    View in: PubMed
    Score: 0.140
  43. Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). Am J Cardiol. 2018 11 15; 122(10):1638-1646.
    View in: PubMed
    Score: 0.139
  44. Real-World Bioresorbable Vascular Scaffold Experience Compared With Second-Generation Metallic Drug-Eluting Stents in Complex Coronary Lesions. J Invasive Cardiol. 2018 07; 30(7):251-255.
    View in: PubMed
    Score: 0.136
  45. Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysis. Int J Cardiol. 2018 07 15; 263:24-28.
    View in: PubMed
    Score: 0.136
  46. Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative. JACC Cardiovasc Interv. 2018 01 08; 11(1):53-65.
    View in: PubMed
    Score: 0.133
  47. Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From a Patient-Level Pooled Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2018 01 08; 11(1):68-76.
    View in: PubMed
    Score: 0.133
  48. Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study. Int J Cardiol. 2017 Nov 01; 246:20-25.
    View in: PubMed
    Score: 0.132
  49. Asymptomatic Large Thrombus Formation in Drug-Eluting Stent 2 Days After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction Patient. JACC Cardiovasc Interv. 2017 12 11; 10(23):2461-2463.
    View in: PubMed
    Score: 0.130
  50. Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JAMA Cardiol. 2017 08 01; 2(8):855-862.
    View in: PubMed
    Score: 0.129
  51. Prevalence, correlates, and impact of coronary calcification on adverse events following PCI with newer-generation DES: Findings from a large multiethnic registry. Catheter Cardiovasc Interv. 2018 04 01; 91(5):859-866.
    View in: PubMed
    Score: 0.129
  52. The Prematurely Stopped Clinical Trial: An Unfinished Symphony. JACC Cardiovasc Interv. 2017 06 26; 10(12):1199-1201.
    View in: PubMed
    Score: 0.129
  53. Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. Int J Cardiol. 2017 Sep 15; 243:132-139.
    View in: PubMed
    Score: 0.127
  54. Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. JACC Cardiovasc Interv. 2017 04 10; 10(7):645-654.
    View in: PubMed
    Score: 0.126
  55. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). Circ Cardiovasc Interv. 2017 02; 10(2).
    View in: PubMed
    Score: 0.125
  56. Efficacy and safety of everolimus and zotarolimus-eluting stents versus first-generation drug-eluting stents in patients with diabetes: A meta-analysis of randomized trials. Int J Cardiol. 2017 Mar 01; 230:310-318.
    View in: PubMed
    Score: 0.124
  57. Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. Am J Cardiol. 2016 Dec 01; 118(11):1661-1668.
    View in: PubMed
    Score: 0.122
  58. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. Am Heart J. 2016 Dec; 182:125-134.
    View in: PubMed
    Score: 0.122
  59. Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JACC Cardiovasc Interv. 2016 09 26; 9(18):1890-901.
    View in: PubMed
    Score: 0.122
  60. Comparative efficacy of coronary artery bypass surgery vs. percutaneous coronary intervention in patients with diabetes and multivessel coronary artery disease with or without chronic kidney disease. Eur Heart J. 2016 Dec 07; 37(46):3440-3447.
    View in: PubMed
    Score: 0.121
  61. Resistant in-stent restenosis in the drug eluting stent era. Catheter Cardiovasc Interv. 2016 Nov; 88(5):777-785.
    View in: PubMed
    Score: 0.119
  62. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis. JACC Cardiovasc Interv. 2016 Apr 11; 9(7):674-84.
    View in: PubMed
    Score: 0.118
  63. Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. Am J Cardiol. 2016 Jun 15; 117(12):1877-83.
    View in: PubMed
    Score: 0.118
  64. Plaque morphology predictors of side branch occlusion after provisional stenting in coronary bifurcation lesion: Results of optical coherence tomography bifurcation study (ORBID). Catheter Cardiovasc Interv. 2017 Feb 01; 89(2):259-268.
    View in: PubMed
    Score: 0.118
  65. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2016 Sep 06; 134(10):e156-78.
    View in: PubMed
    Score: 0.118
  66. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016 09 06; 68(10):1116-39.
    View in: PubMed
    Score: 0.118
  67. Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. Am J Cardiol. 2016 Jun 01; 117(11):1703-13.
    View in: PubMed
    Score: 0.118
  68. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis: From the Women in Innovation and Drug-Eluting Stents Collaborative Patient-Level Pooled Analysis. Circ Cardiovasc Interv. 2016 Jan; 9(1):e002995.
    View in: PubMed
    Score: 0.116
  69. Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol. 2015 Sep 15; 116(6):845-52.
    View in: PubMed
    Score: 0.112
  70. Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry. Circ Cardiovasc Interv. 2015 Jun; 8(6):e001683.
    View in: PubMed
    Score: 0.111
  71. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2015 Apr 07; 65(13):1298-1310.
    View in: PubMed
    Score: 0.109
  72. Comparison of provisional 1-stent and 2-stent strategies in diabetic patients with true bifurcation lesions: the EES bifurcation study. J Invasive Cardiol. 2014 Dec; 26(12):619-23.
    View in: PubMed
    Score: 0.108
  73. Antiplatelet therapy after drug-eluting stent implantation. J Cardiol. 2015 Feb; 65(2):98-104.
    View in: PubMed
    Score: 0.107
  74. Current developments in dual antiplatelet therapy after stenting. Minerva Cardioangiol. 2014 Jun; 62(3):261-76.
    View in: PubMed
    Score: 0.104
  75. Dedicated two-stent technique in complex bifurcation percutaneous coronary intervention with use of everolimus-eluting stents: the EES-bifurcation study. Int J Cardiol. 2014 Jun 01; 174(1):13-7.
    View in: PubMed
    Score: 0.102
  76. Increased thin-cap neoatheroma and periprocedural myocardial infarction in drug-eluting stent restenosis: multimodality intravascular imaging of drug-eluting and bare-metal stents. Circ Cardiovasc Interv. 2013 Oct 01; 6(5):507-17.
    View in: PubMed
    Score: 0.099
  77. Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. Lancet. 2013 Dec 07; 382(9908):1879-88.
    View in: PubMed
    Score: 0.099
  78. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet. 2013 Nov 23; 382(9906):1714-22.
    View in: PubMed
    Score: 0.099
  79. Safety of temporary and permanent suspension of antiplatelet therapy after drug eluting stent implantation in contemporary "real-world" practice. J Interv Cardiol. 2012 Oct; 25(5):482-92.
    View in: PubMed
    Score: 0.091
  80. De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials. Lancet. 2024 Sep 07; 404(10456):937-948.
    View in: PubMed
    Score: 0.053
  81. Ticagrelor monotherapy in patients with diabetes mellitus undergoing percutaneous coronary interventions: insights from the TWILIGHT trial. Cardiovasc Res. 2020 06 01; 116(7):e70-e72.
    View in: PubMed
    Score: 0.039
  82. Impact of high on-treatment platelet reactivity on outcomes following PCI in patients on hemodialysis: An ADAPT-DES substudy. Catheter Cardiovasc Interv. 2020 10 01; 96(4):793-801.
    View in: PubMed
    Score: 0.038
  83. Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. Thromb Haemost. 2019 10; 119(10):1704-1711.
    View in: PubMed
    Score: 0.037
  84. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis. JACC Cardiovasc Interv. 2016 05 23; 9(10):1036-46.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.